Articles tagged "Calcineurin"

2021 American Transplant Congress
Quantifying the Interaction Between Posaconazole and Tacrolimus in Liver Transplant Recipients: A Practical Approach
B. Lane¹, U. Kaszubski¹, A. Freeman¹, B. Wise¹, L. Hutchinson¹, M. Janusek¹, G. Therapondos², H. Bohorquez³, S. Anders¹
¹Pharmacy, Ochsner Medical Center, New Orleans, LA, ²Hepatology, Ochsner Medical Center, New Orleans, LA, ³Transplant Surgery, Ochsner Medical Center, New Orleans, LA
*Purpose: The interaction between tacrolimus (FK) and posaconazole (POSA) is well documented, however the extent of this interaction and the practical management has yet to…
2021 American Transplant Congress
Systematic Evaluation of Immunosuppressant Drug Tolerability in Lung Transplant Recipients with Short Telomere Syndrome
R. Patolia¹, R. Guzy², L. Potter¹
¹Department of Pharmacy, University of Chicago Medicine, Chicago, IL, ²Department of Medicine, Division of Pulmonology, University of Chicago Medicine, Chicago, IL
*Purpose: Lung transplant recipients with short telomere syndrome are at high risk of hematologic complications. Consequently, patients with short telomere syndrome may require more frequent…
2021 American Transplant Congress
Unclear Implications of Tacrolimus Time in Therapeutic Range as a Predictor of Acute Rejection in Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal
D. Pierce, P. West-Thielke, Z. Hajjiri, S. Gaitonde, I. Tzvetanov, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Tacrolimus (TAC) demonstrates a wide intra- and inter-patient variability (IPV) necessitating therapeutic drug monitoring. The purpose of this study is to determine the impact…
2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
W. Asch¹, K. Belfield², V. Do², E. Cohen¹
¹Yale University, New Haven, CT, ²Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…
2021 American Transplant Congress
Cyp3a5 Extensive Metabolizer Phenotype May be Associated with an Increase in Class 2 Donor Specific Antibodies and Antibody-Mediated Rejection
S. Mirza¹, N. Wilson², J. Van Zyl², P. Nguyen², T. Sam², S. Hall², M. Askar², R. Patel²
¹Texas Tech Univeristy Health Sciences Center Jerry H. Hodge School of Pharmacy, Dallas, TX, ²Baylor University Medical Center at Dallas, Dallas, TX
*Purpose: Tacrolimus (TAC) metabolism is highly dependent on CYP3A5, yet there is limited data on the effect of CYP3A5 genetic polymorphisms in heart transplant recipients…
2021 American Transplant Congress
Managing the Significant Drug-Drug Interaction Between Tacrolimus and Letermovir in Solid Organ Transplant Recipients
J. Hedvat, J. Choe, D. Salerno, J. Scheffert, D. Bley, A. Anamisis, T. Shertel, J. Lee, E. Liu, N. W. Lange
NewYork-Presbyterian Hospital, New York, NY
*Purpose: Letermovir does not appear to share cross-resistance with ganciclovir and is not associated with nephrotoxicity or myelosuppressive effects, making it an attractive option for…
2021 American Transplant Congress
Relationship Between Tacrolimus Blood Levels and Covid-19 Pandemic in Kidney Transplant Recipients
T. Inoue¹, K. Unagami,², A. Ishiwatari³, T. Kanzawa³, T. Shimizu³, K. Omoto³, M. Inui³, T. Suzuki¹, H. Ishida⁴, K. Tanabe³
¹Department of Nephrology, Kameda Medical Center, Chiba Kamogawa, Japan, ²Department of Organ Transplant Medicine, Tokyo Women’s Medical University, Tokyo, Japan, ³Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Department of Organ transplant medicine, Tokyo Women’s Medical University, Tokyo, Japan
*Purpose: The novel coronavirus 2019 infection (COVID-19) caused a pandemic, prompting Tokyo, Japan, to restrict on the free movement of people in March 2020. Kidney…
2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
V. R. Peddi¹, B. Marder², L. Gaite³, J. Oberholzer⁴, R. Goldberg⁵, T. Pearson⁶, H. Yang⁷, L. Allamassey⁸, S. Gao⁸, M. Polinsky⁸, R. N. Formica⁹
¹California Pacific Medical Center, San Francisco, CA, ²Colorado Kidney Care, Denver, CO, ³Hospital Marqués de Valdecilla, Cantabria, Spain, ⁴UVA Health, Charlottesville, VA, ⁵Saint Barnabas Medical Center, Livingston, NJ, ⁶Emory University School of Medicine, Atlanta, GA, ⁷UPMC Pinnacle, Harrisburg, PA, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Yale University School of Medicine, New Haven, CT
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering
KFSHRC, Riyadh, Saudi Arabia
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…
2020 American Transplant Congress
Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients
A. D. Leino, K. Abuls, J. L. Rodgers, K. Kuntz
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…